Principles of Patient Assessment

Yearwood, Camille; Guirguis, Lisa M.; Mahmoud, Sherif Hanafy

doi:10.1007/978-3-030-11775-7_2

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early detection of DDIs is essential to establish safe medication use. Multiple efforts could be implemented to proactively reduce DDIs, including the incorporation of the patient care process in prescription reviews [ 18 ], patient counseling, and the use of electronic health records (EHRs) rather than paper records. Additional training for clinical pharmacists regarding the patient care process will improve the detection of DDIs and improve the quality of the provided care.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Drug–Drug Interactions in Primary Care Prescriptions in Egypt: A Cross-Sectional Retrospective Study

Abdelkawy,

Kharouba,

Shendy

et al. 2023

Pharmacy

Self Cite

View full text Add to dashboard Cite

In clinical practice, drug–drug interactions (DDIs) pose significant risks to a large number of patients. Consequently, healthcare providers are required to diligently identify, monitor, and effectively handle these interactions in order to enhance patient outcomes. In Egypt, DDIs are poorly addressed, with no reports for DDIs in primary care. In our cross-sectional, retrospective, observational study, we collected a total of five thousand, eight hundred and twenty prescriptions across eight major governorates in Egypt. Prescriptions were collected over a span of 15 months between 1 June 2021 and 30 September 2022. These prescriptions were analyzed for potential DDIs using the Lexicomp® drug interactions tool. The prevalence of DDIs was found to be 18%, with 22% of the prescriptions having two or more potential DDIs. Moreover, we found 1447 DDIs of categories C (monitoring therapy recommended), D (therapy modification suggested), and X (avoid combination). The most commonly interacting drugs in our study were diclofenac, aspirin, and clopidogrel, while non-steroidal anti-inflammatory drugs (NSAIDs) were the most reported therapeutic class implicated in pharmacologic DDIs. Pharmacodynamic agonistic activity was the most common mechanism of interaction. Therefore, it is crucial to conduct screenings, detect early signs, and closely monitor drug–drug interactions (DDIs) to enhance patients’ overall health outcomes, medication responses, and safety. In this regard, the clinical pharmacist assumes a vital role in implementing these preventive measures.

show abstract

Section: Discussionmentioning

confidence: 99%